Previous 10 | Next 10 |
The growing market of gene therapies enhances Illumina's growth prospects. Illumina has a strong balance sheet opening an opportunity to gain exposure to the rising market of personalized medicine without the risk of investing in biotech. The acquisition of Grail capitalizes on th...
Illumina and its short reading technology pushed the sequencing costs down during the last decade. Long reads and artificial intelligence are improving the sequencing and will likely keep driving the costs lower. Several companies are building business models around these technolo...
PLEASANTON, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming 41st Annual Cowen Health Care Conference. 10x Genomics’ management is scheduled to present on Wednesday, March 3 at 2 p.m. E...
PLEASANTON, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- 10x Genomics , Inc. (Nasdaq: TXG) today detailed a slew of new products and announced the acquisition of Copenhagen-based Tetramer Shop at its inaugural Xperience 2021 event, a showcase with three breakout sessions corresponding ...
4 Top Health Care Stocks To Watch This Week The current pandemic has, no doubt, placed a glaring spotlight on the healthcare industry over the past year. Likewise, investors have been and continue to watch the top healthcare stocks closely. I can imagine that a global health cri...
If you want evidence that investors are excited about genetic testing stocks, just take a look at 10x Genomics (NASDAQ: TXG) . Its shares skyrocketed 86% in 2020 and are up over 30% so far this year. 10x Genomics announced its fourth-quarter and full-year 2020 results after the ...
10x Genomics, Inc. (TXG) Q4 2020 Results Conference Call February 17, 2021 04:30 PM ET Company Participants Serge Saxonov - CEO and Co-Founder Justin McAnear - CFO Brad Crutchfield - Chief Commercial Officer Conference Call Participants Doug Schenkel - Cowen Tejas Savant - Morgan Stanley Deri...
10x Genomics (TXG): Q4 EPS of -$3.87 may not be comparable to consensus of -$0.23.Revenue of $112.2M (+49.0% Y/Y) beats by $11.8M.2021 Financial Guidance: 10x Genomics expects full year 2021 revenue to be in the range of $480 million to $500 million, representing 61% to 67% growth over full y...
Q4 2020 revenue growth of 49% over prior year PLEASANTON, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the fourth quarter and full year ended December 31, 2020 and provides outlook for full year 2021. Recent ...
[[AEL]], [[ALB]], [[ALSN]], [[AM]], [[AR]], [[AXTA]], [[BCOV]], [[BFAM]], [[BIDU]], [[CAKE]], [[CDE]], [[CF]], [[CONE]], [[CYH]], [[ET]], [[FCPT]], [[FSLY]], [[GMED]], [[H]], [[HLF]], [[HPP]], [[IAG]], [[IQ]], [[JACK]], [[KAI]], [[LASR]], [[LOPE]], [[MANT]], [[MOS]], [[MRO]], [[MX]], [[NTR]],...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:00:09 ET Kyle Mikson from Canaccord Genuity issued a price target of $32.00 for TXG on 2024-07-23 05:09:00. The adjusted price target was set to $32.00. At the time of the announcement, TXG was trading at $18.11. The overall price target consensus is at $24...
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024 PR Newswire PLEASANTON, Calif. , July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report fi...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...